What Dimazon Treats: Main Uses and Benefits

Dimazon (Furosemide Injectable) is commonly used to help manage acute conditions characterized by excessive fluid retention and subsequent systemic pressure, providing essential supportive relief. It is generally applied across clinical settings that involve acute or disruptive symptom patterns where supportive symptom management is appropriate.

The active ingredient, Furosemide, is a saluretic indicated for managing oedema associated with cardiac insufficiency, renal dysfunction, trauma, and parasitic disease in target animal species.

Managing Symptomatic Fluid Overload

The medication is relevant for easing symptoms of severe cardiopulmonary congestion, such as labored breathing caused by pulmonary oedema, and is applied in addressing generalized swelling, internal fluid accumulation (ascites), and localized oedema like mammary oedema in cattle. It may also assist in addressing symptomatic manifestations in scenarios like Exercise-Induced Pulmonary Hemorrhage (EIPH) in horses. This supportive relief contributes to easing the overall symptom burden caused by pressure and noticeable physical distension.

“The treatment provides supportive relief that helps patients cope more steadily with difficult episodes of fluid overload.”

---

Quick Fact: Relief for Fluid Congestion

Property	Description
Therapeutic Role	Management of systemic fluid accumulation and related pressure symptoms.
Primary Symptoms	Swelling (oedema), Respiratory Distress from lung fluid, Internal Fluid (Ascites).
Key Benefit	Contributes to improved comfort by reducing the overall fluid burden.
Usage Context	Acute or unstable clinical situations where short-term symptomatic assistance is needed.

Regulatory References

1. Veterinary Medicines Directorate (VMD) data

Dimazon, which contains the active ingredient furosemide, is a potent diuretic primarily used in veterinary medicine for cattle, horses, cats, and dogs. Its main purpose is to treat edema (fluid retention) associated with conditions such as cardiac insufficiency, kidney dysfunction, trauma, and parasitic disease. It is also used for mammary and limb edema.

---

Who Can Use Dimazon?

The product is indicated for the target species listed above to promote diuresis (increased urination) and reduce fluid accumulation.

Target Species
Cattle
Horses
Cats
Dogs

Who Cannot Use Dimazon?

Dimazon is contraindicated and should not be used in animals with certain pre-existing conditions or when used concurrently with specific medications. These contraindications are important for preventing serious adverse effects.

• Acute Glomerular Nephritis (a severe form of kidney inflammation)
• Renal Failure with Anuria (kidney failure where no urine is produced)
• Electrolyte Deficiency Disease (such as low sodium or potassium)
• Overdosage with Digitalis (a class of heart medication)
• Known Hypersensitivity or allergy to the active substance, furosemide, or any of the excipients.

It should also not be used concurrently with aminoglycoside antibiotics due to an increased risk of ototoxicity (ear/hearing damage).

Interactions with other medicines and products

This section outlines the formally documented interaction patterns for Dimazon (Furosemide) as defined in regulatory labeling.

Furosemide's interaction profile is structured around three core regulatory concerns: additive organ toxicity, electrolyte-dependent potentiation of other drugs, and modifications to systemic exposure.

Documented High-Risk Combinations

Co-administration with Aminoglycoside antibiotics (e.g., Gentamicin) and Ethacrynic Acid is contraindicated due to the documented risk of enhanced ototoxicity (hearing damage). Additionally, Furosemide should not be used in cases of Digitalis overdosage.

Pharmacodynamic and Exposure Interactions

Interacting Substance	Officially Documented Interaction Outcome
Cardiac Glycosides (e.g., Digoxin)	Furosemide-induced hypokalaemia may potentiate the toxic effect of the glycoside.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	May antagonize or reduce the diuretic effect of Furosemide.
Lithium	Furosemide reduces Lithium’s renal clearance, leading to increased serum levels and a high risk of toxicity.
Corticosteroids	Concurrent use increases the risk of additive potassium depletion.

Timing and Administration Constraints

Furosemide requires specific administration rules when combined with certain products. Sucralfate must not be taken within 2 hours of Furosemide to prevent reduced absorption. Furthermore, acid solutions, including other parenteral medications, must not be administered concurrently in the same infusion due to documented chemical incompatibility and precipitation risk. Patients with pre-existing conditions such as progressive renal disease or hepatic coma carry a heightened risk of interaction severity, as noted in official prescribing information.

How Dimazon Works

Dimazon functions as a small-molecule inhibitor of farnesyl pyrophosphate synthase ( FPPS), an enzyme critical in the mevalonate pathway within osteoclasts. The active moiety of Dimazon is rapidly internalized by the osteoclast following systemic administration and targets the FPPS catalytic site, preventing the synthesis of isoprenoid lipids. This interaction type is characterized by stable binding to the enzyme.

Inhibition of FPPS halts the prenylation of essential regulatory small GTPases, such as Rac and Rho. This lack of post-translational modification prevents the correct subcellular localization and functional activation of these GTPases. The resulting non-functional GTPases disrupt the osteoclast cytoskeleton and its ability to form a ruffled border, which is necessary for bone resorption.

This cellular cascade leads to the initiation of osteoclast apoptosis (programmed cell death) and reduces the differentiation of precursor cells into mature osteoclasts. The combined effect causes a measurable reduction in overall bone resorption activity within the skeletal system.

Dimazon is administered as an injectable loop diuretic in accordance with standardized protocols. The medication is provided as a 50 mg/ml solution for injection containing Furosemide as the active substance. This formulation dictates a parenteral route of administration.

Administration and Route

The injectable solution is for acute, short-term management and is administered via either the intravenous (IV) or intramuscular (IM) route in dogs and cats. However, IV administration is the required route for cattle and horses. Aseptic precautions must be observed during the injection process.

Official Dosing and Frequency

Dosing is based on the patient's bodyweight and species, and the dose must be adjusted to the individual's response within the approved ranges. The frequency follows an intermittent schedule:

Target Species	Single Dose Range	Frequency/Interval
Horses and Cattle	0.5 to 1.0 mg/kg bodyweight	1 to 2 times daily (6 to 24 hour intervals)
Dogs and Cats (Initial)	2.5 to 5.0 mg/kg bodyweight	At 6 to 8 hour intervals
Dogs and Cats (Maintenance)	1.0 to 2.0 mg/kg bodyweight	At 6 to 8 hour intervals

For severe fluid accumulation in horses and cattle, the single dose may be doubled on a one-time basis.

Usage Context and Duration

The injectable product is intended for acute use and is often used for a short duration, such as not exceeding three days before transitioning to an oral maintenance therapy. A key procedural instruction states that the patient's drinking water should be restricted as much as is clinically possible, as excessive water intake may impair the therapeutic effect of the medication.

Research Evidence / Overview of Studies for Dimazon (Furosemide Injection)

Evidence for Use in Acute Fluid Overload and Oedema (Cardiac and Systemic)

Research for this primary indication was evaluated in conditions associated with acute fluid accumulation, such as pulmonary oedema linked to cardiac insufficiency and generalized swelling. Studies exploring this context include Randomized Controlled Trials (RCTs) and observational studies tracking outcomes related to acute changes. Foundational evidence relies on pharmacodynamic studies which examined the physiological effect of the injection.

The outcomes that researchers examined included physiological responses, such as the volume of urine produced and the rate at which electrolytes were excreted, which monitored the drug's core action. Studies report patterns showing that the injection was observed to affect fluid dynamics through the kidneys. Regulatory data describe patterns where this physiological effect was studied for its relationship to outcomes reflecting physiological strain or stress.

The evidence base for this acute use was observed to have certain limitations. Many older studies are non-comparative, focusing solely on physiological effects. Newer RCTs have explored comparisons between Furosemide and other therapeutic agents to evaluate whether findings were similar or different. Long-term effects are not fully established by these acute studies, which primarily focus on short stabilization intervals.

Evidence for Supportive Use in Exercise-Induced Pulmonary Hemorrhage (EIPH) in Horses

Research concerning the use of the Furosemide injection in racing horses has focused on the supportive management of physiological changes associated with high-speed exercise. This research was primarily conducted through Randomized Controlled Crossover Field Trials.

Studies explored the severity of bleeding in the horse's airways, which was evaluated through measurement using standardized endoscopic scoring systems. Research explored whether the injection was associated with differences in the measured incidence and severity of bleeding scores when compared to placebo, and findings were reported. Findings were mixed across various trials, and some studies indicate that the measured outcomes may have varied across different grades of severity.

Evidence Gaps and Areas of Uncertainty

The available research provides a clear physiological foundation, but certain areas remain uncertain or insufficiently studied. For instance, comparative evidence is lacking in some contexts, making it difficult to fully describe how Furosemide compares to every alternative treatment option. Additionally, many studies have limited follow-up durations, meaning there is limited information for long-term outcomes.

Key Studies & References

1. Dimazon 50 mg/ml Solution for Injection for cattle, horses, cats and dogs - Summary of Product Characteristics (SPC)
2. Furosemide Injection 5% for Animal Use - FDA/DailyMed Labeling Information
3. Furosemide (Salix, Lasix) for Dogs - PetMD
4. Furosemide (Lasix, Salix, Disal) - Veterinary Partner - VIN

Common questions about Dimazon (FAQ)

---

Q: Can herbal supplements affect how Dimazon works?

The official regulatory documents advise keeping a written record of all medications, including dietary supplements and herbal products, to share with the prescribing professional. Official information indicates that non-prescription products may potentially affect how the medicine works or lead to unintended interactions.

---

Q: How long does it typically take to see the effects of Dimazon?

Official product information indicates a rapid onset of the medicine's effect. Following administration via injection, increased urination (diuresis) usually begins within 5 minutes. If administered orally, the onset typically occurs within the first hour.

---

Q: What happens if a person forgets to take a dose of Dimazon?

Regulatory guidance addresses the specific procedure for a forgotten dose. The official product information contains specific instructions on how to proceed if a dose is missed, including warnings about never taking a double dose. These instructions are intended to help maintain the therapeutic schedule.

---

Q: Why might the effect of Dimazon seem to decrease over time?

Studies and official information indicate that the medicine's diuretic effect may sometimes diminish over time during chronic use. Regulatory reviews describe this as a possible 'breaking phenomenon,' caused by the body's adaptive changes in the kidneys in response to the medicine.

---

Q: How long does the active ingredient in Dimazon stay in the system?

The terminal half-life of the active ingredient, Furosemide, is approximately 2 hours in adults. The medicine’s diuretic effect typically lasts for 6 to 8 hours after an oral dose or about 2 hours after an intravenous dose.

---

Q: Does Dimazon need to be taken with food?

Some regulatory sources note that oral Furosemide may be taken with a meal or on an empty stomach. Since Dimazon is supplied as an injectable solution, its parenteral administration (injection) is independent of whether food is consumed.

---

Q: Should Dimazon be taken at a specific time of day?

Regulatory documents suggest that administration of Furosemide is often scheduled for the morning. This specific timing is generally outlined to help manage the risk of nocturia, which is the need to wake up frequently to urinate during the night.

---

Q: Is Dimazon use described for pregnant women in official documents?

Official documents describe that Furosemide is generally reserved for use during pregnancy only if the expected clinical benefit is considered to outweigh the potential risks to the developing fetus. The medicine is also excreted in breast milk, and regulatory information notes it may potentially have an effect on milk production.

---

Q: Are there age restrictions for who can use Dimazon?

Official labeling indicates that the product is suitable for use in pediatric patients, where dosage is calculated based on body weight. However, experience in children and adolescents is limited, and its use is typically recommended only in exceptional, closely monitored circumstances.

---

Q: Can people with diabetes use Dimazon?

Regulatory documents note that Furosemide may have an adverse effect on carbohydrate metabolism, potentially worsening existing diabetes or increasing insulin requirements. Because of this potential risk, official warnings state that regular monitoring of blood glucose levels is necessary during therapy.

---

Q: Where can I find the official regulatory information about Dimazon?

Official regulatory information for the drug can be found on government-run health authority websites. Examples include the FDA DailyMed, the EMA Summary of Product Characteristics (SmPC), or other government-run health authority websites for the specific product.

---

Q: Is Dimazon considered a first-line treatment for edema?

According to the official product information, the injectable form of Dimazon is typically reserved for situations where a quick effect is needed or where taking the medicine orally is not feasible. This suggests it is often prioritized for acute or critical settings rather than initial, non-urgent treatment.

---

Q: Is Dimazon typically used alone or with other medications?

Regulatory documents indicate that Furosemide is frequently used concurrently with other medicines, such as potassium supplements, cardiac glycosides, and various antihypertensive agents. Official warnings note that interaction risk must be considered when other drugs are co-administered.

Storage and Disposal Instructions for Dimazon Solution for Injection

Dimazon (furosemide) solution for injection requires specific conditions to maintain stability.

Storage

The product must not be stored above 25 C and must be kept in the outer carton to protect from light.

• Cold Storage Warning: Prolonged storage below 18 C may cause crystalline precipitation, and the solution must not be used while crystals are present. Crystals may be re-dissolved by a specific warming procedure outlined in the label.
• Post-Opening Stability: Following the first opening of the vial, the solution must be used within twenty-eight days.
• Child Safety: The product must be stored out of the sight and reach of children.

Disposal

Any unused medicine or waste materials must be disposed of in accordance with local requirements. Official documents prohibit disposal via wastewater or household waste, requiring the use of take-back schemes.